ValuEngine upgraded shares of Acura Pharmaceuticals (OTCMKTS:ACUR) from a strong sell rating to a sell rating in a report released on Friday morning.

Shares of Acura Pharmaceuticals (OTCMKTS ACUR) opened at $0.38 on Friday. Acura Pharmaceuticals has a twelve month low of $0.35 and a twelve month high of $1.40. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.23 and a quick ratio of 1.23.

Acura Pharmaceuticals (OTCMKTS:ACUR) last announced its quarterly earnings results on Monday, November 13th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter. Acura Pharmaceuticals had a negative net margin of 36.20% and a negative return on equity of 231.18%. The company had revenue of $0.08 million during the quarter.

TRADEMARK VIOLATION WARNING: This report was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://theolympiareport.com/2017/12/05/acura-pharmaceuticals-acur-upgraded-to-sell-by-valuengine.html.

About Acura Pharmaceuticals

Acura Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Acura Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acura Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.